Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WP1220 in Mycosis Fungoides
NCT04702503Phase 1Completed
- Sponsor
- Moleculin Biotech, Inc.
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of WP1220 in mycosis fungoides (MF), sponsored by Moleculin Biotech, Inc. Primary endpoint: Evaluation of the safety profile of WP1220 applied topically at 12 weeks. Started Mar 2019; status: completed.
02
Drugs
WP1220
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT04702503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702503.